Pseudohallucinations associated with moclobemide: a case report.
The goal of the multicenter drug surveillance project AMSP ("Arzneimittelsicherheit in der Psychiatrie") is the monitoring, assessment and analysis of adverse drug reactions (ADR) of psychopharmalogical drugs. We report about a 23 year-old patient with a depressive episode. He developed severe pseudohallucinations under a treatment with moclobemide. The symptoms occur 6 days after starting the medication and decline within two days after stopping moclobemide. The term "pseudohallucinations" is discussed controversially but still of high interest.
Degner
D
D
Department of Psychiatry and Psychotherapy, Georg-August University of Göttingen, Germany. ddegner@gwdg.de
Kropp
S
S
Porzig
J
J
Grohmann
R
R
Rüther
E
E
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy; D006212:Hallucinations / Q000139:chemically induced* / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078785:Mirtazapine; D020912:Moclobemide / Q000009:adverse effects* / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D020280:Sertraline / Q000627:therapeutic use
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D008803:Mianserin; D000078785:Mirtazapine; D020912:Moclobemide; D020280:Sertraline